Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Well-differentiated Neuroendocrine Tumors”

124 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 124 results

Testing effectiveness (Phase 2)Study completedNCT04318561
What this trial is testing

Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Peking Union Medical College Hospital 40
Early research (Phase 1)Active Not RecruitingNCT04750954
What this trial is testing

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Neoplasm
National Cancer Institute (NCI) 29
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT00654238
What this trial is testing

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

Who this might be right for
Metastatic Differentiated Thyroid CancerMetastatic Poorly Differentiated Thyroid CancerMetastatic Anaplastic Thyroid Cancer+1 more
University of Pennsylvania 59
Testing effectiveness (Phase 2)Study completedNCT02698410
What this trial is testing

Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.

Who this might be right for
Neuroendocrine Tumours
Ipsen 40
Testing effectiveness (Phase 2)Study completedNCT00381641
What this trial is testing

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Who this might be right for
Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaRefractory Thyroid Gland Carcinoma+16 more
National Cancer Institute (NCI) 63
Testing effectiveness (Phase 2)WithdrawnNCT02108782
What this trial is testing

Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors

Who this might be right for
GastrinomaGlucagonomaInsulinoma+3 more
Academic and Community Cancer Research United
Testing effectiveness (Phase 2)Study completedNCT03591731
What this trial is testing

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

Who this might be right for
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique 185
Not applicableStudy completedNCT03176485
What this trial is testing

Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors

Who this might be right for
Metastatic CancerMelanomaColon Cancer+6 more
University of Arizona 45
Very early researchUnknownNCT02823691
What this trial is testing

The MetNET-2 Trial

Who this might be right for
Neuroendocrine Tumors
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 20
Post-approval studies (Phase 4)Study completedNCT02842749
What this trial is testing

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Who this might be right for
Pancreatic Neuroendocrine Tumors
Novartis Pharmaceuticals 61
Not applicableStudy completedNCT04365023
What this trial is testing

Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors

Who this might be right for
Neuroendocrine Tumors
Assistance Publique - Hôpitaux de Paris 168
Testing effectiveness (Phase 2)Active Not RecruitingNCT04759911
What this trial is testing

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Who this might be right for
Malignant Thyroid Gland NeoplasmPoorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland Carcinoma+4 more
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)UnknownNCT02294006
What this trial is testing

Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs

Who this might be right for
Well Differentiated Pancreatic Endocrine Tumor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 26
Testing effectiveness (Phase 2)UnknownNCT01118065
What this trial is testing

Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer

Who this might be right for
Head and Neck Cancer
Leiden University Medical Center 42
Testing effectiveness (Phase 2)Study completedNCT03870399
What this trial is testing

Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

Who this might be right for
Neuroendocrine TumorsProgesterone Receptor Positive TumorEstrogen Receptor Positive Tumor
AC Camargo Cancer Center 23
Testing effectiveness (Phase 2)Study completedNCT02806648
What this trial is testing

A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

Who this might be right for
Pancreatic Neuroendocrine Cancer
Grupo Espanol de Tumores Neuroendocrinos 21
Early research (Phase 1)Active Not RecruitingNCT04234568
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Who this might be right for
Metastatic Digestive System Neuroendocrine NeoplasmMetastatic Neuroendocrine Tumor
National Cancer Institute (NCI) 31
Very early researchEnded earlyNCT03001349
What this trial is testing

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Who this might be right for
MeningiomaMetastatic Well Differentiated Neuroendocrine NeoplasmMultiple Endocrine Neoplasia Type 1+3 more
M.D. Anderson Cancer Center 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT03891784
What this trial is testing

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Who this might be right for
Advanced Digestive System Neuroendocrine NeoplasmDigestive System Neuroendocrine TumorForegut Neuroendocrine Tumor+6 more
University of Washington 20
Next Page
116